Business Context and Reporting Period
This Form 8-K was filed by Oragenics, Inc. on July 14, 2016. The report addresses a regulatory notice from NYSE MKT LLC regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on listing status and regulatory compliance rather than financial performance data.
Material Changes
The material change reported is the acceptance by NYSE Regulation of the Company's plan to regain compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE MKT Company Guide. Previously, the Company was notified of non-compliance regarding stockholders' equity standards on May 13, 2016, and additional standards on June 21, 2016.
Outlook, Risks, and Contingencies
- Compliance Deadline: The Company must regain compliance by November 10, 2017.
- Delisting Risk: If the Company fails to meet the standards by the deadline or does not make progress consistent with the plan, NYSE Regulation may initiate delisting proceedings.
- Current Status: The common stock will continue to trade on the NYSE MKT under the symbol "OGEN.BC" subject to periodic review.
- Management Action: A plan of compliance was submitted on June 10, 2016, and accepted on July 14, 2016.
Investor Verification Checklist
- Verify the specific initiatives outlined in the Company's plan of compliance submitted on June 10, 2016.
- Monitor periodic reviews by NYSE MKT to ensure the Company is making progress consistent with the plan.
- Confirm the Company's stockholders' equity levels in subsequent filings to assess progress toward the November 10, 2017 deadline.
- Review the press release dated July 19, 2016 (Exhibit 99.1) for additional details on the acceptance notice.